story of the week
Pembrolizumab Plus Lenalidomide and Dexamethasone in Patients With Treatment-Naïve Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Plus Lenalidomide and Dexamethasone for Patients With Treatment-Naive Multiple Myeloma (KEYNOTE-185): A Randomised, Open-Label, Phase 3 Trial
Lancet Haematol 2019 Jul 18;[EPub Ahead of Print], SZ Usmani, F Schjesvold, A Oriol, L Karlin, M Cavo, RM Rifkin, HA Yimer, R LeBlanc, N Takezako, RD McCroskey, ABM Lim, K Suzuki, H Kosugi, G Grigoriadis, I Avivi, T Facon, S Jagannath, S Lonial, RU Ghori, MZH Farooqui, P Marinello, J San-MiguelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.